Karakan Tarkan, Cindoruk Mehmet, Degertekin Bulent, Dogan Ibrahim, Sancak Alper, Dumlu Sukru, Gorgul Ahmet, Unal Selahattin
Gastroenterology Department, Gozi University, Faculty of Medicine, Ankara, Turkey.
Curr Ther Res Clin Exp. 2005 May;66(3):247-53. doi: 10.1016/j.curtheres.2005.06.002.
Isolated thrombocytopenia is a common manifestation of hepatitis C virus (HCV) infection. There is no established treatment modality for this condition. The efficacy of standard interferon (IFN) monotherapy has been reported in some studies. The major disadvantage of this treatment is the high rate of recurrence due to viral breakthrough during the first 12 weeks of treatment. Pegylated IFNs are now the standard regimen for chronic hepatic disease due to HCV infection. However, due to a lack of evidence, pegylated IFNs are not widely used for HCV-related isolated thrombocytopenia.
The aim of this report was to present the case of a male patientwith severe symptomatic thrombocytopenia due to HCV infection.
Thrombocytopenia was treated with pegylated IFN plus ribavirin.
Although standard IFN monotherapy failed to achieve virologic and hematologic improvement, therapy with pegylated IFN alfa-2a plus ribavirin was associated with both virologic and hematologic improvement without any significant adverse effects.
Pegylated IFN plus ribavirin was effective in this patient for thetreatment of HCV-related thrombocytopenia. However, further research is needed to define the response rate in different patient populations.
孤立性血小板减少是丙型肝炎病毒（HCV）感染的常见表现。针对这种情况尚无既定的治疗方式。一些研究报道了标准干扰素（IFN）单药治疗的疗效。这种治疗的主要缺点是在治疗的前12周因病毒突破导致复发率高。聚乙二醇化干扰素现在是HCV感染所致慢性肝病的标准治疗方案。然而，由于缺乏证据，聚乙二醇化干扰素未广泛用于HCV相关的孤立性血小板减少症。
本报告旨在介绍一例因HCV感染导致严重症状性血小板减少的男性患者病例。
采用聚乙二醇化干扰素加利巴韦林治疗血小板减少症。
尽管标准干扰素单药治疗未能实现病毒学和血液学改善，但聚乙二醇化α-2a干扰素加利巴韦林治疗与病毒学和血液学改善相关，且无任何明显不良反应。
聚乙二醇化干扰素加利巴韦林对该患者治疗HCV相关血小板减少症有效。然而，需要进一步研究来确定不同患者群体的反应率。
